286 related articles for article (PubMed ID: 20063989)
1. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets.
Bambace NM; Levis JE; Holmes CE
Platelets; 2010; 21(2):85-93. PubMed ID: 20063989
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of PAR-1 or PAR-4 promotes similar pattern of VEGF and endostatin release and pro-angiogenic responses mediated by human platelets.
Etulain J; Mena HA; Negrotto S; Schattner M
Platelets; 2015; 26(8):799-804. PubMed ID: 26082997
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
Holmes CE; Huang JC; Pace TR; Howard AB; Muss HB
Clin Cancer Res; 2008 May; 14(10):3070-6. PubMed ID: 18483373
[TBL] [Abstract][Full Text] [Related]
4. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
5. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF
Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550
[TBL] [Abstract][Full Text] [Related]
6. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy.
Rozalski M; Nocun M; Watala C
Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207
[TBL] [Abstract][Full Text] [Related]
7. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors.
Baurand A; Eckly A; Bari N; Léon C; Hechler B; Cazenave JP; Gachet C
Thromb Haemost; 2000 Sep; 84(3):484-91. PubMed ID: 11019976
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of species differences in the platelet ADP and thrombin response.
Nylander S; Mattsson C; Lindahl TL
Thromb Res; 2006; 117(5):543-9. PubMed ID: 15921723
[TBL] [Abstract][Full Text] [Related]
9. Cangrelor attenuates coated-platelet formation.
Norgard NB; Hann CL; Dale GL
Clin Appl Thromb Hemost; 2009; 15(2):177-82. PubMed ID: 18796456
[TBL] [Abstract][Full Text] [Related]
10. Effects of P2Y(1) and P2Y(12) receptor antagonists on ADP-induced shape change of equine platelets: comparison with human platelets.
Mateos-Trigos G; Evans RJ; Heath MF
Platelets; 2002; 13(5-6):285-92. PubMed ID: 12189014
[TBL] [Abstract][Full Text] [Related]
11. The P2 receptors in platelet function.
Hechler B; Cattaneo M; Gachet C
Semin Thromb Hemost; 2005 Apr; 31(2):150-61. PubMed ID: 15852218
[TBL] [Abstract][Full Text] [Related]
12. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
Frelinger AL; Jakubowski JA; Li Y; Barnard MR; Fox ML; Linden MD; Sugidachi A; Winters KJ; Furman MI; Michelson AD
Thromb Haemost; 2007 Jul; 98(1):192-200. PubMed ID: 17598013
[TBL] [Abstract][Full Text] [Related]
13. Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation.
Nylander S; Mattsson C; Ramström S; Lindahl TL
Br J Pharmacol; 2004 Aug; 142(8):1325-31. PubMed ID: 15265806
[TBL] [Abstract][Full Text] [Related]
14. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.
Fagura MS; Dainty IA; McKay GD; Kirk IP; Humphries RG; Robertson MJ; Dougall IG; Leff P
Br J Pharmacol; 1998 May; 124(1):157-64. PubMed ID: 9630355
[TBL] [Abstract][Full Text] [Related]
15. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release.
Ma L; Elliott SN; Cirino G; Buret A; Ignarro LJ; Wallace JL
Proc Natl Acad Sci U S A; 2001 May; 98(11):6470-5. PubMed ID: 11353854
[TBL] [Abstract][Full Text] [Related]
16. Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
Kobsar AL; Koessler J; Rajkovic MS; Brunner KP; Steigerwald U; Walter U
Platelets; 2010; 21(2):112-6. PubMed ID: 20085435
[TBL] [Abstract][Full Text] [Related]
17. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.
Dovlatova N; Wijeyeratne YD; Fox SC; Manolopoulos P; Johnson AJ; White AE; Latif ML; Ralevic V; Heptinstall S
Thromb Haemost; 2008 Aug; 100(2):261-70. PubMed ID: 18690346
[TBL] [Abstract][Full Text] [Related]
18. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
19. Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589.
Johnson FL; Boyer JL; Leese PT; Crean C; Krishnamoorthy R; Durham T; Fox AW; Kellerman DJ
Platelets; 2007 Aug; 18(5):346-56. PubMed ID: 17654304
[TBL] [Abstract][Full Text] [Related]
20. P2 receptors, platelet function and pharmacological implications.
Gachet C
Thromb Haemost; 2008 Mar; 99(3):466-72. PubMed ID: 18327393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
